Ironwood Pharmaceuticals (IRWD) Hisse Özeti
Bir biyoteknoloji şirketi olan Ironwood Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda gastrointestinal (GI) ve nadir hastalıklara yönelik tedavilerin geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 3/6 |
| Finansal Sağlık | 1/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
IRWD Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ironwood Pharmaceuticals, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$3.91 |
| 52 Haftanın En Yüksek Seviyesi | US$5.78 |
| 52 Haftanın En Düşük Seviyesi | US$0.71 |
| Beta | 0.21 |
| 1 Aylık Değişim | -5.33% |
| 3 Aylık Değişim | -6.90% |
| 1 Yıllık Değişim | 389.42% |
| 3 Yıllık Değişim | -64.74% |
| 5 Yıllık Değişim | -70.54% |
| Halka arzdan bu yana değişim | -66.44% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 21
IRWD: Pediatric Approval And 2026 Outlook Will Support Future Upside
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $10.00 to $11.00, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E to support the new price target. What’s in the News for Ironwood Pharmaceuticals The U.S. FDA approved an expanded LINZESS (linaclotide) indication for pediatric patients 2 years and older with functional constipation, making it the only FDA approved prescription therapy specifically for pediatric functional constipation, according to company disclosures.Seeking Alpha • Jul 13
Ironwood: Linzess Buys Time, But Apraglutide's rNPV Doesn't Close The Gap
Summary Ironwood Pharmaceuticals (IRWD) faces a looming Linzess patent cliff in 2029, with generics poised to erode its main revenue stream. Apraglutide, acquired for $1B, is unlikely to fully offset Linzess losses due to mixed Phase 3 data, regulatory delays, and a small addressable market. Apraglutide’s risk-adjusted NPV is estimated at $461M, well below IRWD’s enterprise value, and further delays could reduce this value significantly. I initiate coverage with a cautious Hold, as IRWD appears cheap but justified by limited pipeline prospects and significant execution risks. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jul 06
IRWD: Expanded Pediatric Use And Earnings Outlook Will Drive Upside Potential
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $4.85 to $6.10. This change reflects updated assumptions on the discount rate, revenue growth, profit margin, and future P/E levels.Recent updates
Anlatı Güncellemesi • Jul 21
IRWD: Pediatric Approval And 2026 Outlook Will Support Future Upside
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $10.00 to $11.00, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E to support the new price target. What’s in the News for Ironwood Pharmaceuticals The U.S. FDA approved an expanded LINZESS (linaclotide) indication for pediatric patients 2 years and older with functional constipation, making it the only FDA approved prescription therapy specifically for pediatric functional constipation, according to company disclosures.Seeking Alpha • Jul 13
Ironwood: Linzess Buys Time, But Apraglutide's rNPV Doesn't Close The Gap
Summary Ironwood Pharmaceuticals (IRWD) faces a looming Linzess patent cliff in 2029, with generics poised to erode its main revenue stream. Apraglutide, acquired for $1B, is unlikely to fully offset Linzess losses due to mixed Phase 3 data, regulatory delays, and a small addressable market. Apraglutide’s risk-adjusted NPV is estimated at $461M, well below IRWD’s enterprise value, and further delays could reduce this value significantly. I initiate coverage with a cautious Hold, as IRWD appears cheap but justified by limited pipeline prospects and significant execution risks. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jul 06
IRWD: Expanded Pediatric Use And Earnings Outlook Will Drive Upside Potential
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $4.85 to $6.10. This change reflects updated assumptions on the discount rate, revenue growth, profit margin, and future P/E levels.Anlatı Güncellemesi • Jun 22
IRWD: Expanded Constipation Indication And 2026 Outlook Will Support Future Upside
Analysts have modestly revised their price target for Ironwood Pharmaceuticals to $10.00, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E. These revisions leave their fair value estimate unchanged at $10.00.
Anlatı Güncellemesi • Jun 08
IRWD: Pediatric Expansion And Stable Guidance Will Support Future Upside Potential
Analysts have adjusted their $ price target on Ironwood Pharmaceuticals, reflecting updated assumptions for discount rate, revenue growth, profit margins, and future P/E, and are now framing the stock's valuation through a more measured growth outlook. What's in the News The U.S. FDA approved LINZESS (linaclotide) for functional constipation in pediatric patients 2 to 5 years old, expanding the prior indication that started at age 6 and keeping LINZESS as the only FDA approved prescription therapy for pediatric functional constipation, according to the company.Anlatı Güncellemesi • May 25
IRWD: Maintained 2026 Revenue Outlook Will Support Long Term Cash Flows
Analysts have kept their price target for Ironwood Pharmaceuticals steady at $10.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that they view as better aligned with the company’s current risk and earnings profile. What's in the News Chief Financial Officer Gregory Martini plans to resign effective May 15, 2026.Analiz Makalesi • May 11
Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
A week ago, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) came out with a strong set of quarterly numbers that could...Anlatı Güncellemesi • May 01
IRWD: Earnings Outlook And Trial Updates Will Limit Future Share Upside
Analysts have slightly adjusted their price target on Ironwood Pharmaceuticals, citing updated assumptions for discount rate, revenue growth, profit margins, and future P/E, while keeping their fair value estimate broadly unchanged at $3.70. What's in the News Ironwood plans to present data from the LANDMARK survey at the 2026 Digestive Disease Week meeting in Chicago, highlighting healthcare professional views on the burden of total parenteral nutrition for short bowel syndrome and preferred attributes for new therapies that reduce dependence on parenteral support (company announcement).Anlatı Güncellemesi • Apr 17
IRWD: Extended Revenue Guidance And Margin Assumptions Will Restrain Future Upside
Analysts have slightly adjusted their price target on Ironwood Pharmaceuticals, reflecting small tweaks to inputs such as discount rate, revenue growth assumptions, profit margin outlook and the future P/E multiple, while keeping their overall fair value estimate steady at $3.70. What's in the News Ironwood Pharmaceuticals reiterated its earnings guidance for 2026, stating that total revenue is expected to be in the range of $450 million to $475 million.Anlatı Güncellemesi • Apr 02
IRWD: Multi Year Revenue Guidance And Margin Assumptions Will Shape Outlook
Analysts have raised their price target on Ironwood Pharmaceuticals by $3, reflecting updated assumptions around fair value, a lower discount rate, higher projected revenue growth, a materially stronger profit margin outlook, and a reduced future P/E multiple. What's in the News Ironwood Pharmaceuticals reiterated earnings guidance for 2026, with total revenue expected in the range of $450 million to $475 million (company guidance).Anlatı Güncellemesi • Mar 19
IRWD: Reinforced 2026 Guidance And Legal Resolution Will Support Future Cash Flows
Analysts have modestly adjusted their price target on Ironwood Pharmaceuticals, now reflecting a $10.00 fair value that aligns with updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Ironwood Pharmaceuticals reiterated earnings guidance for 2026, with total revenue expected in a range of $450 million to $475 million.Anlatı Güncellemesi • Mar 05
IRWD: Index Inclusion And Reinforced Guidance Will Support Future Cash Flows
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $8.00 to $10.00, citing updated assumptions for revenue growth, profit margins, and future P/E expectations built into their models. What's in the News Ironwood Pharmaceuticals reiterated its 2026 earnings guidance, with total revenue expected in a range of $450 million to $475 million.Anlatı Güncellemesi • Feb 19
IRWD: Medicare Pricing Clarity Will Support Future Cash Flows And Optionality
Analysts have raised their price target on Ironwood Pharmaceuticals to $3.80 from $1.70, citing clearer visibility on future Linzess pricing after the Centers for Medicare and Medicaid Services set a negotiated $136 Medicare price for a 30 day supply. They view this as supportive of the company as it reviews alternatives.Anlatı Güncellemesi • Feb 05
IRWD: Medicare Pricing Clarity And Revenue Outlook Will Shape Balanced Share Prospects
Ironwood Pharmaceuticals' analyst price target has moved higher, with the fair value estimate shifting from about US$2.50 to roughly US$4.85. Analysts cite updated revenue growth, profit margin and future P/E assumptions, along with recent Medicare pricing clarity for Linzess, as key drivers of their revised view.Anlatı Güncellemesi • Jan 22
IRWD: Medicare Pricing Clarity Will Support Future Earnings And Deal Optionality
Narrative Update Overview Analysts have raised their price target for Ironwood Pharmaceuticals to US$3.80 from US$1.70, citing clearer visibility on future Linzess Medicare pricing following the recent Inflation Reduction Act negotiation outcomes. Analyst Commentary Bullish analysts are highlighting the recent Medicare pricing outcome for Linzess as an important input into their updated view on Ironwood Pharmaceuticals.Anlatı Güncellemesi • Jan 07
IRWD: Medicare Price Certainty Will Support Stronger Earnings And Optionality
Analysts have lifted their 12 month fair value estimate for Ironwood Pharmaceuticals from $3.80 to $8.00, citing clearer Medicare pricing for Linzess and what they view as a stronger setup as the company reviews potential alternatives. Analyst Commentary Recent research has focused on how clearer Medicare pricing for Linzess could affect Ironwood Pharmaceuticals' valuation and options review.Analiz Makalesi • Jan 06
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have continued their recent momentum with a 32% gain in the last...Anlatı Güncellemesi • Dec 13
IRWD: Medicare Pricing Clarity Will Support More Predictable Earnings And Balanced Outlook
Analysts have lifted their price target on Ironwood Pharmaceuticals to $3.80 from $1.70, citing improved visibility on Linzess Medicare pricing that supports higher long term profitability. This, they say, justifies a lower discount rate, a more stable revenue outlook, and a richer fair value assessment.Anlatı Güncellemesi • Nov 28
IRWD: Future Share Price Could Weaken Amid Upcoming Medicare Price Cuts
Analysts have increased their price target for Ironwood Pharmaceuticals to $3.80 from $1.70. They cite greater clarity on future Medicare pricing and strategic opportunities following recent policy announcements.Anlatı Güncellemesi • Nov 13
IRWD: Future Expectations May Not Justify Recent Share Price Levels
Analysts have raised their price target for Ironwood Pharmaceuticals from $0.95 to $1.85. They cited improved revenue growth projections, a reduced discount rate, and a substantial increase in expected profit margins.Analiz Makalesi • Nov 12
Need To Know: Analysts Are Much More Bullish On Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenues
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders will have a reason to smile today, with the analysts making...Analiz Makalesi • Nov 06
There's No Escaping Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Muted Revenues Despite A 39% Share Price Rise
Despite an already strong run, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have been powering on, with a gain...Anlatı Güncellemesi • Oct 29
Worsening Revenue Outlook Will Limit Upside Despite Improving Profit Margins
Analysts have lowered their price target for Ironwood Pharmaceuticals from $0.95 to $0.95, citing reduced revenue growth expectations. This has been offset by improved profit margins and a lower discount rate.Analiz Makalesi • Sep 10
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 33% But Its Business Prospects Need A Lift Too
Despite an already strong run, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have been powering on, with a gain...Analiz Makalesi • Jun 25
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Held Back By Insufficient Growth Even After Shares Climb 28%
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders are no doubt pleased to see that the share price has...Analiz Makalesi • Dec 21
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders would be excited to see that the share price has had a...Analiz Makalesi • Oct 24
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 1.6x Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) is...
Yeni Anlatı • Sep 17
LINZESS And Apraglutide Set To Power Through Market Challenges With Strong Growth Prospects
LINZESS prescription growth indicates strong market acceptance, potentially increasing revenue as it gains market share.Analiz Makalesi • Aug 16
Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There
The market seemed underwhelmed by the solid earnings posted by Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) recently...Analiz Makalesi • Jun 27
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 2.4x Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) is...Seeking Alpha • Jun 20
Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Summary Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024. The global primary biliary cholangitis therapeutics market size is projected to reach $1.4 billion by 2032. NDA filing and other regulatory filings across the globe of apraglutide for the treatment of patients with short bowel syndrome who are dependent on parenteral support. Ironwood Pharmaceuticals had cash and cash equivalents of $121.5 million as of March 31st of 2024; Enough cash to fund its operations for at least the next 12 months. Read the full article on Seeking AlphaHissedar Getirileri
| IRWD | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 1.6% | 0.09% | -0.7% |
| 1Y | 389.4% | 31.4% | 15.3% |
Getiri vs. Endüstri: IRWD geçen yıl % 31.4 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: IRWD geçen yıl % 15.3 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| IRWD volatility | |
|---|---|
| IRWD Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: IRWD son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: IRWD 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1998 | 100 | Tom McCourt | ironwoodpharma.com |
Bir biyoteknoloji şirketi olan Ironwood Pharmaceuticals Inc., Amerika Birleşik Devletleri'nde ve uluslararası alanda gastrointestinal (GI) ve nadir hastalıklara yönelik tedavilerin geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Kabızlık veya kronik idiyopatik kabızlık ile birlikte irritabl bağırsak sendromundan muzdarip yetişkinlerin tedavisi için bir guanilat siklaz tip-C (GC-C) agonisti olan linaklotidin yanı sıra fonksiyonel kabızlıktan muzdarip pediatrik hastalar için LINZESS ve CONSTELLA isimleri altında satmaktadır. Şirket ayrıca interstisyel sistit/mesane ağrısı sendromu ve endometriozis dahil olmak üzere visseral ağrı durumlarının tedavisi için bir GC-C agonisti olan IW-3300'ü ve parenteral desteğe bağımlı kısa bağırsak sendromu hastaları ve akut graft versus host hastalığı için glukagon benzeri peptid-2'nin uzun etkili bir sentetik peptid analoğu olan Apraglutide'i geliştirmektedir.
Ironwood Pharmaceuticals, Inc. Temel Bilgiler Özeti
| IRWD temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$610.72m |
| Kazançlar(TTM) | US$102.18m |
| Gelir(TTM) | US$361.51m |
6.3x
F/K Oranı1.8x
P/S OranıIRWD aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| IRWD gelir tablosu (TTM) | |
|---|---|
| Gelir | US$361.51m |
| Gelir Maliyeti | US$89.64m |
| Brüt Kâr | US$271.87m |
| Diğer Giderler | US$169.69m |
| Kazançlar | US$102.18m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 0.62 |
| Brüt Marj | 75.20% |
| Net Kâr Marjı | 28.26% |
| Borç/Özkaynak Oranı | -269.3% |
IRWD uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/27 14:50 |
| Gün Sonu Hisse Fiyatı | 2026/07/27 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Ironwood Pharmaceuticals, Inc. 26 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Geoffrey Meacham | Barclays |
| Patrick Trucchio | Berenberg |
| David Maris | BMO Capital Markets Equity Research |